The John Martin Foundation concentrates on translational global health and biomedical research with an emphasis on improving access to treatments in low- and middle-income settings. Its major gifts fund drug development and disease-specific research (notably malaria, liver disease, and antimicrobials), health systems interventions that expand maternal and child care access, and policy work to accelerate access to medicines. Grants are large and programmatic, often targeted to applied research centers, implementation pilots, and licensing/policy initiatives that can enable broader uptake of medical innovations.
The John Martin Foundation’s recent giving is defined by large, programmatic investments in translational global health and biomedical research. One of its biggest commitments supports a $2.5 million center in West Bengal for liver research and innovations, showing how the foundation backs applied science alongside clinical capacity. Another major line of work funds malaria drug development, including a $2 million grant to The Scripps Research Institute for a single-dose cure and 28-day chemoprophylaxis to eradicate malaria. The foundation also supports access-to-medicine efforts, from antimicrobial subscription models to voluntary licensing and policy work aimed at lowering barriers to essential treatments. Across the portfolio, the John Martin Foundation combines research, implementation, and systems change. Its grants reach universities, hospitals, research foundations, and global health intermediaries, often for projects designed to move evidence into practice. In liver disease, the foundation has backed both center-building and disease-specific research, including NAFLD and hepatitis-related work. In infectious disease, it supports hepatitis B treatment scale-up, surveillance, and elimination networks, while also funding community-oriented programs in maternal and child health and underserved settings. The pattern is not small exploratory support; it is grantmaking at a scale that can underwrite centers, registries, pilot models, and field implementation.
Liver disease is a consistent theme. The foundation gave $1.5 million to The Regents of the University of California San Diego for the UC San Diego Non-Alcoholic Fatty Liver Disease (NAFLD) Research Center, and $2.5 million to Liver Foundation West Bengal for the John C. Martin Centre for Liver Research and Innovations. It also funded hepatitis-related infrastructure and analysis, including work on hepatitis B transmission and treatment. In malaria, the foundation supported drug development directly through a $2 million grant to The Scripps Research Institute for MCMQ069 as a single-dose cure and 28-day chemoprophylaxis to eradicate malaria. Access to medicines is another clear thread: President and Fellows of Harvard College received $898,691 for work on voluntary licensing and a path to accelerate access to medicines, while Health Innovation and Investment Exchange received $65,000 for identifying opportunities and challenges in voluntary licensing in Southeast Asia. The portfolio also includes health system and community delivery projects, such as financing and mobile technology in Kenya and maternal and child healthcare through m-TIBA care bundles.
$10M
$29.7M
$2.1M
$11M
Most grants fall between $100K and $1M, with a median of $300K.
25th Percentile
$100K
Median
$300K
75th Percentile
$1M
About 29% of grants go to recipients in GA.
Top 8 recipient countries by grant volume for John Martin Foundation.
| Rank | Country | Grants | Total | Share |
|---|---|---|---|---|
| 1 | United StatesDomestic | 46 | $43.9M | 39.0% |
| 2 | Netherlands |
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Concentrated, high-value grants (several multi-million-dollar awards) to a small number of strategic partners; a mix of repeat funding to research institutions and one-off large grants for implementation pilots and policy work across global sites.
Notable grantees: The Scripps Research Institute, PharmAccess Foundation, Liver Foundation West Bengal, University of California San Diego (Regents), ArandaOrg Inc
The John Martin Foundation’s typical grant size is $100,000 at the 25th percentile, $300,000 at the median, and $1,000,000 at the 75th percentile, indicating a portfolio built around sizeable program grants. The same organizations appear across multiple years in several cases, including PharmAccess Foundation, Integral Global Consulting, The Scripps Research Institute, and Vestfold Hospital, which suggests recurring support for selected initiatives rather than one-time awards. The foundation is classified as a regular funder, not a DAF or program-related investment vehicle. Unsolicited applications are not indicated in the provided program descriptions, and several active programs explicitly note that they do not accept unsolicited requests.
Grant recipients are spread nationally, with the highest concentration in Georgia by grant count. The HQ state, California, accounts for 29% of grants to recipients in the recent dataset, but the giving footprint extends well beyond it. Recent grants reached cities including La Jolla, New York, Atlanta, Cambridge, Lahore, Islamabad, Geneva, Vancouver, Buenos Aires, and West Bengal. Outside the United States, the recipient-country distribution includes Norway, the Netherlands, Eswatini, India, Argentina, Canada, and Switzerland.
Its recent grants focus on translational global health and biomedical research, especially malaria drug development, liver disease and hepatitis programs, access to medicines, and health system interventions. Examples in the dataset include malaria cure development, NAFLD research, hepatitis B treatment scale-up, and voluntary licensing work to improve access to medicines.
The typical grant size is $100,000 at the 25th percentile, $300,000 at the median, and $1,000,000 at the 75th percentile. That distribution shows that many awards are substantial program grants rather than small project checks.
Yes. Several recipients appear across multiple years in the recent grant list, including PharmAccess Foundation, Integral Global Consulting, The Scripps Research Institute, and Vestfold Hospital. That pattern points to repeated support for ongoing projects and programs.
The top state by grant count is Georgia. California is the HQ state and receives 29% of grants to recipients in the dataset, while recipients also appear in cities such as La Jolla, New York, Atlanta, Cambridge, Geneva, Vancouver, Buenos Aires, and West Bengal.
It has supported voluntary licensing and pharmaceutical access policy, including a $898,691 grant to President and Fellows of Harvard College for work on voluntary licensing and a $65,000 grant to Health Innovation and Investment Exchange for analysis of voluntary licensing opportunities and challenges in Southeast Asia.
2026
Source: IRS Form 990-PF, fiscal year 2026.
| 19 |
| $23.1M |
16.1% |
| 3 | Switzerland | 15 | $3.4M | 12.7% |
| 4 | Norway | 14 | $6.1M | 11.9% |
| 5 | Argentina | 8 | $665K | 6.8% |
| 6 | India | 7 | $14.2M | 5.9% |
| 7 | Canada | 5 | $750K | 4.2% |
| 8 | China | 4 | $1M | 3.4% |
Recipient country reflects the grantee's headquarters per IRS 990-PF and Schedule F filings, not the program's implementation country.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| INSTITUTE OF HUMAN VIROLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE | BALTIMORE, MD | $5,500,000 | 2026 | ENDOWMENTS IN HONOR OF JOHN C. MARTIN AT INSTITUTE OF HUMAN VIROLOGY: A.IHV CHAIR PROFESSORSHIP $5 MILLION; B. IHV ANNUAL LECTURESHIP $500,000 |
| MYRIAD USA INC | NEW YORK, NY | $1,500,000 | 2026 | AMERICAN FRIENDS OF CAPRISA |
| ARANDA ORG INC | NEW YORK, NY | $1,250,000 | 2026 | EXTENDING THE ARANDA MODEL AND ENHANCING STEWARDSHIP AND SURVEILLANCE SERVICE TO NEW COUNTRIES |
| THE SCRIPPS RESEARCH INSTITUTE | LA JOLLA, CA | $1,000,000 | 2026 | CLINICAL PROOF-OF-CONCEPT OF AN AFFORDABLE, ORAL CANCER IMMUNOTHERAPY (OX-4224) IN INDIA FOR LOW- AND MIDDLE-INCOME COUNTRIES |
| CENTER FOR DISEASE ANALYSIS FOUNDATION INC | LAFAYETTE, CO | $1,000,000 | 2026 | POLARIS OBSERVATORY TO SUPPORT HEPATITIS ELIMINATION |
| PHARMACCESS FOUNDATION | AMSTERDAM | $1,000,000 | 2026 | IMPROVE QUALITY OF MATERNAL AND CHILDCARE THROUGH M-TIBA CARE BUNDLES |
| INTEGRAL GLOBAL CONSULTING | ATLANTA, GA | $394,478 | 2026 | LINKAGE TO CARE AND HEALTH EDUCATION IN UNDERSERVED COMMUNITIES OF ISLAMABAD, PAKISTAN |
| THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | PALO ALTO, CA | $250,000 | 2026 | SUPPORT FOR ASIAN LIVER CENTER 2024-2027 |
| THE SCRIPPS RESEARCH INSTITUTE | LA JOLLA, CA | $250,000 | 2026 | AMENDED: ENDOWED GRADUATE FELLOWSHIPS |
| TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION | DECATUR, GA | $238,563 | 2026 | UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS 2025-2027 |
| INTEGRAL GLOBAL CONSULTING | ATLANTA, GA | $236,348 | 2026 | MITIGATION THE SPREAD OF COVID-19 AMONG GARMENT FACTORY AND TEXTILE MILL POPULATIONS IN BANGLADESH: PHASE II TRANSLATING RESULTS INTO SUSTAINED SECTOR PRACTICE |
| WORLD HEPATITIS ALLIANCE | GENEVA | $150,000 | 2026 | COMMUNITY IMPACT PROGRAMME |
| THE GLOBAL HEPATITIS ASSOCIATION | TORONTO | $150,000 | 2026 | 19TH INTERNATIONAL SYMPOSIUM OF VIRAL HEPATITIS & LIVER DISEASES - GLOBAL HEPATITIS SUMMIT 2025 |
| TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION | DECATUR, GA | $150,000 | 2026 | UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS |
| SOCIETY ON LIVER DISEASE IN AFRICA | UTRECHT | $58,771 | 2026 | CONFERENCE ON LIVER DISEASE IN AFRICA |
| ICALMA | BUENOS AIRES | $50,880 | 2026 | ANTIMICROBIAL RESISTANCE PATTERNS OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS: A SURVEILLANCE PROJECT FROM ARGENTINA AND URUGUAY |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $2,500,000 | 2025 | JOHN C. MARTIN ENDOWED CHAIR IN LIVER DISEASE FOR ROHIT LOOMBA |
| LIVER FOUNDATION WEST BENGAL | KOLKATA, WE | $2,000,000 | 2025 | JOHN C MARTIN CENTER FOR LIVER RESEARCH AND INNOVATION |
| THE SCRIPPS RESEARCH INSTITUTE | LA JOLLA, CA | $1,500,000 | 2025 | CLINICAL PROOF-OF-CONCEPT OF AN AFFORDABLE, ORAL CANCER IMMUNOTHERAPY (OX-4224) IN INDIA FOR LOW- AND MIDDLE-INCOME COUNTRIES |
| MYRIAD USA INC | NEW YORK, NY | $1,500,000 | 2025 | AMERICAN FRIENDS OF CAPRISA |
| ARANDA ORG INC | NEW YORK, NY | $1,250,000 | 2025 | EXTENDING THE ARANDA MODEL AND ENHANCING STEWARDSHIP AND SURVEILLANCE SERVICE TO NEW COUNTRIES |
| CENTER FOR DISEASE ANALYSIS FOUNDATION INC | LAFAYETTE, CO | $1,000,000 | 2025 | POLARIS OBSERVATORY TO SUPPORT HEPATITIS ELIMINATION |
| PHARMACCESS FOUNDATION | AMSTERDAM | $1,000,000 | 2025 | IMPROVE QUALITY OF MATERNAL AND CHILDCARE THROUGH M-TIBA CARE BUNDLES |
| VESTFOLD HOSPITAL | TONSBERG | $600,000 | 2025 | HEPSANET: A COLLABORATIVE HEPATITIS B REGISTRY IN AFRICA |
| INTEGRAL GLOBAL CONSULTING | ATLANTA, GA | $500,000 | 2025 | LINKAGE TO CARE AND HEALTH EDUCATION IN UNDERSERVED COMMUNITIES OF ISLAMABAD, PAKISTAN |
| ARANDA ORG INC | NEW YORK, NY | $500,000 | 2025 | PILOTING THE ARANDA SUBSCRIPTION MODEL FOR ACCESS TO ANTIMICROBIALS IN BOTSWANA |
| PHARMACCESS FOUNDATION | AMSTERDAM | $489,815 | 2025 | AMENDED - PAVING THE WAY FOR UHC IN KISUMU THROUGH A DATA-DRIVEN APPROACH |
| INSTITUTE OF HUMAN VIROLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE | BALTIMORE, MD | $300,000 | 2025 | ASSESSMENT OF LONG-ACTING AMPHETAMINES TO REDUCE HARM IN METHAMPHETAMINE USE DISORDER (ALARM) |
| WORLD HEPATITIS ALLIANCE | GENEVA | $250,000 | 2025 | WORLD HEPATITIS SUMMIT 2024 |
| WORLD HEPATITIS ALLIANCE | GENEVA | $150,000 | 2025 | COMMUNITY IMPACT PROGRAMME |
| TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION | DECATUR, GA | $150,000 | 2025 | UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS |
| ASIAN LIVER CENTER | PALO ALTO, CA | $113,983 | 2025 | HBV-CONNECT: STRENGTHENING HEALTHCARE CAPACITIES FOR PREVENTION, SCREENING, AND CARE OF HEPATITIS B IN VIETNAM |
| ICALMA | BUENOS AIRES | $50,880 | 2025 | ANTIMICROBIAL RESISTANCE PATTERNS OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS: A SURVEILLANCE PROJECT FROM ARGENTINA AND URUGUAY |
| SOCIETY ON LIVER DISEASE IN AFRICA | UTRECHT | $50,000 | 2025 | CONFERENCE ON LIVER DISEASE IN AFRICA (COLDA) 2024 |
| THE SCRIPPS RESEARCH INSTITUTE | LA JOLLA, CA | $2,000,000 | 2024 | MCMQ069 AS A SINGLE-DOSE CURE AND 28-DAY CHEMOPROPHYLAXIS TO ERADICATE MALARIA |
| ARANDAORG INC | NEW YORK, NY | $2,000,000 | 2024 | PILOTING THE ARANDA SUBSCRIPTION MODEL FOR ACCESS TO ANTIMICROBIALS IN BOTSWANA |
| THE SCRIPPS RESEARCH INSTITUTE | LA JOLLA, CA | $2,000,000 | 2024 | MCMQ069 AS A SINGLE-DOSE CURE AND 28-DAY CHEMOPROPHYLAXIS TO ERADICATE MALARIA |
| PHARM ACCESS FOUNDATION | AMSTERDAM | $1,000,000 | 2024 | THE JOURNEY TOWARDS UHC: KISUMU COUNTY AS A KENYAN MODEL FOR SOCIAL HEALTH INSURANCE AND BETTER HEALTH |
| PHARM ACCESS FOUNDATION | AMSTERDAM | $1,000,000 | 2024 | IMPROVE QUALITY OF MATERNAL AND CHILDCARE THROUGH M-TIBA CARE BUNDLES |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $1,000,000 | 2024 | UC SAN DIEGO NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) RESEARCH CENTER |
| INTEGRAL GLOBAL CONSULTING | NE ATLANTA, GA | $500,000 | 2024 | LINKAGE TO CARE AND HEALTH EDUCATION IN UNDERSERVED COMMUNITIES OF ISLAMABAD, PAKISTAN |
| KING BAUDOUIN FOUNDATION UNITED STATES INC | NEW YORK, NY | $300,000 | 2024 | THE GLOBAL HEALTH DIPLOMATS PODCAST: PROPOSAL TO HONOR THE MEMORY OF JOHN C. MARTIN |
| INTEGRAL GLOBAL CONSULTING | NE ATLANTA, GA | $300,000 | 2024 | MITIGATION THE SPREAD OF COVID-19 AMONG GARMENT FACTORY AND TEXTILE MILL POPULATIONS IN BANGLADESH: PHASE II TRANSLATING RESULTS INTO SUSTAINED SECTOR PRACTICE |
| VESTFOLD HOSPITAL | TONSBERG | $270,240 | 2024 | HEPATITIS B IN SUB-SAHARAN AFRICA: SCALING UP TREATMENT IN ETHIOPIA |
| VESTFOLD HOSPITAL | TONSBERG | $230,000 | 2024 | HEPSANET: A COLLABORATIVE HEPATITIS B REGISTRY IN AFRICA |
| MCI GROUP CANADA | VANCOUVER | $150,000 | 2024 | 18TH INTERNATIONAL SYMPOSIUM OF VIRAL HEPATITIS & LIVER DISEASES (ISVHLD) GLOBAL HEPATITIS SUMMIT 2023 |
| TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION (CG | DECATUR, GA | $150,000 | 2024 | UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS |
| WORLD HEPATITIS ALLIANCE | GENEVA | $150,000 | 2024 | COMMUNITY IMPACT PROGRAMME |
| HEALTH INNOVATION AND INVESTMENT EXCHANGE (HIEX) | GENEVA | $65,000 | 2024 | TOWARDS ACCESS TO MEDICINE IN THE SOUTHEAST ASIA REGION IDENTIFYING POTENTIAL OPPORTUNITIES AND CHALLENGES IN IMPLEMENTING VOLUNTARY LICENSING FOR ACCESS TO MEDICINE (VLAM) IN THE SOUTHEAST ASIA REGION |
| ICALMA | BUENOS AIRES | $50,880 | 2024 | ANTIMICROBIAL RESISTANCE PATTERNS OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS: A SURVEILLANCE PROJECT FROM ARGENTINA AND URUGUAY |
INSTITUTE OF HUMAN VIROLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
$5,500,000ENDOWMENTS IN HONOR OF JOHN C. MARTIN AT INSTITUTE OF HUMAN VIROLOGY: A.IHV CHAIR PROFESSORSHIP $5 MILLION; B. IHV ANNUAL LECTURESHIP $500,000
MYRIAD USA INC
$1,500,000AMERICAN FRIENDS OF CAPRISA
ARANDA ORG INC
$1,250,000EXTENDING THE ARANDA MODEL AND ENHANCING STEWARDSHIP AND SURVEILLANCE SERVICE TO NEW COUNTRIES
THE SCRIPPS RESEARCH INSTITUTE
$1,000,000CLINICAL PROOF-OF-CONCEPT OF AN AFFORDABLE, ORAL CANCER IMMUNOTHERAPY (OX-4224) IN INDIA FOR LOW- AND MIDDLE-INCOME COUNTRIES
CENTER FOR DISEASE ANALYSIS FOUNDATION INC
$1,000,000POLARIS OBSERVATORY TO SUPPORT HEPATITIS ELIMINATION
PHARMACCESS FOUNDATION
IMPROVE QUALITY OF MATERNAL AND CHILDCARE THROUGH M-TIBA CARE BUNDLES
INTEGRAL GLOBAL CONSULTING
$394,478LINKAGE TO CARE AND HEALTH EDUCATION IN UNDERSERVED COMMUNITIES OF ISLAMABAD, PAKISTAN
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
$250,000SUPPORT FOR ASIAN LIVER CENTER 2024-2027
THE SCRIPPS RESEARCH INSTITUTE
$250,000AMENDED: ENDOWED GRADUATE FELLOWSHIPS
TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION
$238,563UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS 2025-2027
INTEGRAL GLOBAL CONSULTING
$236,348MITIGATION THE SPREAD OF COVID-19 AMONG GARMENT FACTORY AND TEXTILE MILL POPULATIONS IN BANGLADESH: PHASE II TRANSLATING RESULTS INTO SUSTAINED SECTOR PRACTICE
WORLD HEPATITIS ALLIANCE
$150,000COMMUNITY IMPACT PROGRAMME
THE GLOBAL HEPATITIS ASSOCIATION
$150,00019TH INTERNATIONAL SYMPOSIUM OF VIRAL HEPATITIS & LIVER DISEASES - GLOBAL HEPATITIS SUMMIT 2025
TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION
$150,000UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS
SOCIETY ON LIVER DISEASE IN AFRICA
$58,771CONFERENCE ON LIVER DISEASE IN AFRICA
ICALMA
$50,880ANTIMICROBIAL RESISTANCE PATTERNS OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS: A SURVEILLANCE PROJECT FROM ARGENTINA AND URUGUAY
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
$2,500,000JOHN C. MARTIN ENDOWED CHAIR IN LIVER DISEASE FOR ROHIT LOOMBA
LIVER FOUNDATION WEST BENGAL
$2,000,000JOHN C MARTIN CENTER FOR LIVER RESEARCH AND INNOVATION
THE SCRIPPS RESEARCH INSTITUTE
$1,500,000CLINICAL PROOF-OF-CONCEPT OF AN AFFORDABLE, ORAL CANCER IMMUNOTHERAPY (OX-4224) IN INDIA FOR LOW- AND MIDDLE-INCOME COUNTRIES
MYRIAD USA INC
$1,500,000AMERICAN FRIENDS OF CAPRISA
ARANDA ORG INC
$1,250,000EXTENDING THE ARANDA MODEL AND ENHANCING STEWARDSHIP AND SURVEILLANCE SERVICE TO NEW COUNTRIES
CENTER FOR DISEASE ANALYSIS FOUNDATION INC
$1,000,000POLARIS OBSERVATORY TO SUPPORT HEPATITIS ELIMINATION
PHARMACCESS FOUNDATION
$1,000,000IMPROVE QUALITY OF MATERNAL AND CHILDCARE THROUGH M-TIBA CARE BUNDLES
VESTFOLD HOSPITAL
$600,000HEPSANET: A COLLABORATIVE HEPATITIS B REGISTRY IN AFRICA
INTEGRAL GLOBAL CONSULTING
$500,000LINKAGE TO CARE AND HEALTH EDUCATION IN UNDERSERVED COMMUNITIES OF ISLAMABAD, PAKISTAN
ARANDA ORG INC
$500,000PILOTING THE ARANDA SUBSCRIPTION MODEL FOR ACCESS TO ANTIMICROBIALS IN BOTSWANA
PHARMACCESS FOUNDATION
$489,815AMENDED - PAVING THE WAY FOR UHC IN KISUMU THROUGH A DATA-DRIVEN APPROACH
INSTITUTE OF HUMAN VIROLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
$300,000ASSESSMENT OF LONG-ACTING AMPHETAMINES TO REDUCE HARM IN METHAMPHETAMINE USE DISORDER (ALARM)
WORLD HEPATITIS ALLIANCE
$250,000WORLD HEPATITIS SUMMIT 2024
WORLD HEPATITIS ALLIANCE
$150,000COMMUNITY IMPACT PROGRAMME
TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION
$150,000UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS
ASIAN LIVER CENTER
$113,983HBV-CONNECT: STRENGTHENING HEALTHCARE CAPACITIES FOR PREVENTION, SCREENING, AND CARE OF HEPATITIS B IN VIETNAM
ICALMA
$50,880ANTIMICROBIAL RESISTANCE PATTERNS OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS: A SURVEILLANCE PROJECT FROM ARGENTINA AND URUGUAY
SOCIETY ON LIVER DISEASE IN AFRICA
$50,000CONFERENCE ON LIVER DISEASE IN AFRICA (COLDA) 2024
THE SCRIPPS RESEARCH INSTITUTE
$2,000,000MCMQ069 AS A SINGLE-DOSE CURE AND 28-DAY CHEMOPROPHYLAXIS TO ERADICATE MALARIA
ARANDAORG INC
$2,000,000PILOTING THE ARANDA SUBSCRIPTION MODEL FOR ACCESS TO ANTIMICROBIALS IN BOTSWANA
THE SCRIPPS RESEARCH INSTITUTE
$2,000,000MCMQ069 AS A SINGLE-DOSE CURE AND 28-DAY CHEMOPROPHYLAXIS TO ERADICATE MALARIA
PHARM ACCESS FOUNDATION
$1,000,000THE JOURNEY TOWARDS UHC: KISUMU COUNTY AS A KENYAN MODEL FOR SOCIAL HEALTH INSURANCE AND BETTER HEALTH
PHARM ACCESS FOUNDATION
$1,000,000IMPROVE QUALITY OF MATERNAL AND CHILDCARE THROUGH M-TIBA CARE BUNDLES
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
$1,000,000UC SAN DIEGO NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) RESEARCH CENTER
INTEGRAL GLOBAL CONSULTING
$500,000LINKAGE TO CARE AND HEALTH EDUCATION IN UNDERSERVED COMMUNITIES OF ISLAMABAD, PAKISTAN
KING BAUDOUIN FOUNDATION UNITED STATES INC
$300,000THE GLOBAL HEALTH DIPLOMATS PODCAST: PROPOSAL TO HONOR THE MEMORY OF JOHN C. MARTIN
INTEGRAL GLOBAL CONSULTING
$300,000MITIGATION THE SPREAD OF COVID-19 AMONG GARMENT FACTORY AND TEXTILE MILL POPULATIONS IN BANGLADESH: PHASE II TRANSLATING RESULTS INTO SUSTAINED SECTOR PRACTICE
VESTFOLD HOSPITAL
$270,240HEPATITIS B IN SUB-SAHARAN AFRICA: SCALING UP TREATMENT IN ETHIOPIA
VESTFOLD HOSPITAL
$230,000HEPSANET: A COLLABORATIVE HEPATITIS B REGISTRY IN AFRICA
MCI GROUP CANADA
$150,00018TH INTERNATIONAL SYMPOSIUM OF VIRAL HEPATITIS & LIVER DISEASES (ISVHLD) GLOBAL HEPATITIS SUMMIT 2023
TASK FORCE FOR GLOBAL HEALTH COALITION FOR GLOBAL HEPATITIS ELIMINATION (CG
$150,000UN GROUP OF FRIENDS TO ELIMINATE HEPATITIS
WORLD HEPATITIS ALLIANCE
$150,000COMMUNITY IMPACT PROGRAMME
HEALTH INNOVATION AND INVESTMENT EXCHANGE (HIEX)
$65,000TOWARDS ACCESS TO MEDICINE IN THE SOUTHEAST ASIA REGION IDENTIFYING POTENTIAL OPPORTUNITIES AND CHALLENGES IN IMPLEMENTING VOLUNTARY LICENSING FOR ACCESS TO MEDICINE (VLAM) IN THE SOUTHEAST ASIA REGION
ICALMA
$50,880ANTIMICROBIAL RESISTANCE PATTERNS OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS: A SURVEILLANCE PROJECT FROM ARGENTINA AND URUGUAY